Font Size:

Risk Assessment

The Risk Assessment Team at Fox Chase Cancer Center

The Department of Clinical Genetics

History Timeline

See a timeline
of our progress

A leader in cancer prevention and risk assessment, Fox Chase Cancer Center established one of the first risk programs in the country in 1991 for individuals with a family history of breast and/or ovarian cancer. This program served as a model for others around the country and led to risk assessment services at Fox Chase for other types of cancers including prostate, GI and lung cancers as well as melanoma.

Today, our Department of Clinical Genetics builds on this pioneering spirit to offer the most comprehensive risk assessment program in the Philadelphia region. It encompasses all of Fox Chase’s clinical services for healthy people at risk for cancer, as well as innovative research in the areas of cancer prevention and genetics.


Mary B. Daly, MD, PhD, FACP

Mary B. Daly, MD, PhD, FACP
Chair, Department of Clinical Genetics
Timothy R. Talbot Jr. Chair for Cancer Research
Co-Leader, Keystone Program in
Personalized Risk and Prevention

Dr. Daly is the Chair of the Department of Clinical Genetics. Her main focus is women's health. Dr. Daly is the founder of the Margaret Dyson Family Risk Assessment Program, evaluating preventive approaches to breast and ovarian cancer. Her primary areas of research include the epidemiologic and genetic aspects of breast and ovarian cancer, and the translation of this information into effective cancer prevention.

Hossein Borghaei, DO

Hossein Borghaei, DO
Director, Lung Cancer Risk
Dr. Borghaei’s clinical expertise is in lung cancer, lymphoma (T and B cells), monoclonal antibody, targeted therapy, and immunotherapy cancer vaccine. His research is focused on the production of monoclonal antibodies against novel targets in tumor blood vessels.

Michael Hall, MD

Michael J. Hall, MD
Director, Gastrointestinal Risk
Dr. Hall specializes in cancers of the gastrointestinal (GI) tract, with a specific interest in pancreas, small bowel, and colon tumors. Dr. Hall's recent research has focused on the risk of pancreatic cancer in BRCA 1/2 mutation carriers, risk communication, racial/ethnic disparities in genetic testing, and the costs and benefits of pharmacogenomic and other genetic testing in the treatment of cancer.

Elias Obeid, MD, MPH

Elias Obeid, MD, MPH
Assistant Professor, Breast, Ovarian, and Prostate Cancer Risk
Dr. Obeid is an expert in breast cancer, cancer risk assessment and prevention, hereditary cancer syndromes and medical ethics. He stresses the focus Fox Chase places on working as a team to individualize the care of every patient, as a member of the risk assessment program (RAP) and the breast cancer service line.

Risk Assesment Nursing Team

Agnes Masny, RN, MPH, MSN, CRNP (left);
Sharon Schwartz, MSN, CRNP;
Sue Montgomery, BSN, RN, GCN

Nursing Team

The Risk Assessment Program Nurses perform a variety of roles in research and clinical care of high risks patients. The nurses provide cancer risk assessment, education and counseling. They help evaluate family and medical history and, if appropriate help coordinate genetic testing. The nurses also see patients in our high risk clinics for medical management, cancer screening and risk reduction.

Genetic Counselors

(from left to right) Michelle Savage, Kim Rainey, Andrea Forman, Sue Montgomery

Genetic Counselors

Your genetic counselor will review your medical and family history in order to determine the personal and possibly inherited factors that could affect your risk to develop certain cancers.  They will help you understand the influence of these different risk factors and help to coordinate genetic testing, if appropriate.